tiprankstipranks
Trending News
More News >
Grail Inc (GRAL)
:GRAL
US Market
Advertisement

GRAIL Inc (GRAL) Earnings Dates, Call Summary & Reports

Compare
306 Followers

Earnings Data

Report Date
Feb 19, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-3.05
Last Year’s EPS
-2.89
Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reveals robust revenue growth, significant clinical trial successes, and strategic international expansion, supported by a strong financial position. However, the company continues to face financial losses and potential regulatory delays.
Company Guidance
During the GRAIL Third Quarter 2025 Earnings Call, management provided guidance featuring several key metrics. GRAIL reported a 39% growth in Gallery test volumes and a 29% increase in revenue for 2025. Overall revenue for the third quarter was $36.2 million, with screening revenue contributing $32.8 million, a 29% increase from the previous year. The company sold over 45,000 Gallery tests in the third quarter, indicating strong demand despite typical seasonal fluctuations. GRAIL also highlighted a positive strategic collaboration with Samsung to expand into Asian markets, alongside a $110 million equity investment from Samsung. Additionally, GRAIL completed a $325 million private placement, enhancing their cash and investment position to approximately $850 million, excluding the Samsung investment. Looking forward, GRAIL updated its cash burn guidance for 2025 to no more than $290 million, a significant improvement from previous figures, with a cash runway extending into 2030. The company is focused on achieving FDA approval for Gallery and pursuing broad reimbursement in 2026, with anticipated clinical and regulatory milestones including the completion of their PMA submission to the FDA in 2026 and full clinical utility results from the NHS Gallery study.
Strong Revenue Growth
Revenue for Q3 2025 was $36.2 million, up $7.5 million or 26% compared to 2024. Screening revenue increased by 29% and U.S. Gallery revenue was up 28% year-over-year.
Significant Clinical Trial Results
The PATHFINDER II study showed a more than sevenfold increase in overall cancer detection rate, with Gallery's positive predictive value (PPV) at 61.6% and specificity at 99.6%.
Successful Financial Strategy
Completed a $325 million private placement, strengthening the balance sheet. Cash and investments are approximately $850 million, extending the cash runway into 2030.
International Expansion
Announced a strategic collaboration with Samsung to commercialize Gallery in South Korea and potentially other Asian markets.
Operational Efficiency
Non-GAAP adjusted gross profit increased by 60% compared to 2024, with a gross margin of 55% due to improvements in lab efficiency and cost management.
Encouraging SIMPLIFY Study Outcomes
Updated PPV in symptomatic populations increased to 84.2%, with long-term follow-up showing many initially false positives were later diagnosed with cancer.

GRAIL Inc (GRAL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

GRAL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 19, 2026
2025 (Q4)
-3.05 / -
-2.89
Nov 12, 2025
2025 (Q3)
-3.37 / -2.46
-3.9437.56% (+1.48)
Aug 12, 2025
2025 (Q2)
-3.57 / -3.18
-51.05593.77% (+47.88)
May 13, 2025
2025 (Q1)
-3.99 / -3.10
-7.0556.03% (+3.95)
Feb 20, 2025
2024 (Q4)
-4.97 / -2.89
-6.03952.14% (+3.15)
Nov 12, 2024
2024 (Q3)
-6.43 / -3.94
-28.71186.28% (+24.77)
Aug 13, 2024
2024 (Q2)
- / -51.05
-6.217-721.22% (-44.84)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

GRAL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$84.77$83.20-1.85%
Aug 12, 2025
$33.60$33.98+1.13%
May 13, 2025
$42.89$32.89-23.32%
Feb 20, 2025
$47.76$40.73-14.72%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Grail Inc (GRAL) report earnings?
Grail Inc (GRAL) is schdueled to report earning on Feb 19, 2026, After Close (Confirmed).
    What is Grail Inc (GRAL) earnings time?
    Grail Inc (GRAL) earnings time is at Feb 19, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is GRAL EPS forecast?
          GRAL EPS forecast for the fiscal quarter 2025 (Q4) is -3.05.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis